Merck found not liable in federal Vioxx case

Share this article:
A New Orleans jury today handed Merck a victory in its latest federal Vioxx trial. The jury ruled that the drug maker adequately warned of the risks associated with the medicine. The lawsuit was filed by plaintiff Anthony Wayne Dedrick, 50, of Waynesboro, TN, who argued that his heart attack resulted from Merck failing to warn doctors adequately about the risk posed by taking the withdrawn painkiller Vioxx. Today’s ruling brings Merck’s federal Vioxx case win total to four. In state courts, Merck has won three and lost three cases. Jurors in a case in New Jersey decided in Merck’s favor, but the judge later ordered a retrial.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...